First Tracks Biotherapeutics, Inc.NASDAQ: TRAX

First Tracks Biotherapeutics Announces Participation in September Investor Conferences

· Issued by First Tracks Biotherapeutics, Inc. via GlobeNewswire

Summary by 6ix AI

First Tracks Biotherapeutics, a clinical-stage biotechnology company developing antibody therapies for autoimmune and inflammatory diseases, said members of its executive team are scheduled to take part in three investor conferences in September 2026.

Key details

  • 21st Annual Wells Fargo Healthcare Conference, Boston: fireside chat and one-on-one investor meetings on Wednesday, September 9, 2026 at 9:30am ET / 6:30am PT.
  • Citi's 2026 Biopharma Back to School Conference, New York City: one-on-one investor meetings on Thursday, September 10, 2026.
  • Morgan Stanley 24th Annual Global Healthcare Conference, New York City: one-on-one investor meetings on Wednesday, September 16, 2026.
  • A live webcast of the fireside chat will be available on the investor section of the First Tracks website, with a replay available for at least 30 days after the event.

6ix AI wrote this summary from the release below and checked it against the release.

SAN DIEGO, Aug. 26, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical-stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases, today announced that members of its executive team are scheduled to participate in multiple upcoming investor conferences:

21st Annual Wells Fargo Healthcare Conference, Boston

  • Format – Fireside chat and one-on-one investor meetings

  • Date and Time – Wednesday, Sept. 9, 2026 at 9:30am ET / 6:30am PT

Citi's 2026 Biopharma Back to School Conference, New York City

  • Format – One-on-one investor meetings

  • Date and Time – Thursday, Sept. 10, 2026

Morgan Stanley 24th Annual Global Healthcare Conference, New York City

  • Format – One-on-one investor meetings

  • Date and Time – Wednesday, Sept. 16, 2026

A live webcast of the fireside chat will be available on the investor section of the First Tracks website at https://ir.firsttracksbio.com/news-events/events. A replay of the webcast will be available for at least 30 days following the event.

About First Tracks Biotherapeutics

First Tracks Biotherapeutics is a clinical stage biotechnology company advancing antibody therapies that modulate immune pathways implicated in autoimmune and inflammatory diseases. Its pipeline includes ANB033, a CD122 antagonist in development for celiac disease and eosinophilic esophagitis; rosnilimab, a pathogenic T cell depleter in development for rheumatoid arthritis; and ANB101, a BDCA2 modulator. To learn more, visit www.FirstTracksBio.com or follow us on LinkedIn.

Investor Contact:
Nick Montemarano
Vice President, Investor Relations
858.732.0178
[email protected]

First Tracks Biotherapeutics, Inc. on 6ix

Story so far

Earlier from First Tracks Biotherapeutics

Later from First Tracks Biotherapeutics

All First Tracks Biotherapeutics news releases